Biora’s BT-600 novel drug-device may revolutionise targeted colon therapy
Biora Therapeutics recently announced the initiation of phase 1 clinical trials of BT-600, a novel drug-device combination for ulcerative colitis (UC) patients.
Archives for February 22, 2024
MIP Discovery raises £7m to drive commercialization in cell and gene space
MIP Discovery, a developer of non-biological affinity reagents designed to accelerate the production of cell and gene therapies, has closed a £7 million Series A financing round, led by Mercia Ventures.
Bristol Myers Squibb invests over $400m in sterile drug product facility
Bristol Myers Squibb is investing over $400 million to build a sterile drug product facility at its Dublin campus.